Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

418 results about "Lectin" patented technology

Lectins are carbohydrate-binding proteins that are highly specific for sugar groups of other molecules. Lectins have a role in recognition on the cellular and molecular level and play numerous roles in biological recognition phenomena involving cells, carbohydrates, and proteins. Lectins also mediate attachment and binding of bacteria and viruses to their intended targets.

Antimicrobial surfaces and uses thereof in cell cultures

The present invention relates to a cell culture vessel characterized in that it comprises an inner surface on which one or more lectins suitable for binding to one or more species of microorganisms are immobilized. Furthermore, the invention refers to a method for cultivating cells comprising contacting the cell culture medium comprising the cells with a surface that bears immobilized lectin and to the use of immobilized lectin for reducing the microorganism contamination in a cell culture contacted with such surface.
Owner:THE CULTIVATED B GMBH

System and method for mapping molecules into interfaces

PCT designated stage expiredWO2025123146A1Molecular designData visualisationReceptorAntibody antigen
Embodiments described herein relate to systems and methods for mapping molecules into interfaces. An example interface includes a visual interface having a map visualization. Example molecules include proteins, or any protein-like molecules or fragments thereof such as antibodies, antigens, proteins, lectins, receptors. Embodiments described herein relate to systems and methods for mapping molecules into interfaces by processing data using dimensionality reduction to generation representations of molecule maps (e.g. map visualizations).
Owner:KISOJI BIOTECHNOLOGY INC

Preparation method of ulinastatin crude product

The invention discloses a preparation method of an ulinastatin crude product, which comprises the following steps: a, adsorbing urine of healthy adults by using macroporous adsorption resin, and then desorbing by using a salt solution to obtain an eluent; b, carrying out ultrafiltration concentration on the obtained eluent to obtain a first concentrated solution; c, purifying and eluting the concentrated solution obtained in the step b by using a lectin affinity chromatography column, and collecting a liquid phase; d, performing ultrafiltration concentration on the obtained liquid phase to obtain a second concentrated solution; and e, salting out the second concentrated solution, and filtering to obtain the ulinastatin crude product. The ulinastatin prepared by the preparation method disclosed by the invention is high in specific activity and long in shelf life.
Owner:JIANGSU AIDEA PHARMACEUTICAL CO LTD +1

Nano-drug delivery system capable of entering brain through nose and targeting central nervous system as well as preparation method and application of nano-drug delivery system

The invention relates to the technical field of biological medicine, and particularly discloses a nano-drug delivery system entering brain through nose and targeting central nervous and a preparation method and application thereof. The nano-drug delivery system capable of entering the brain through the nose and targeting the central nervous system comprises a biological treatment drug and lectin coupled liposome nano-particles wrapping the surface of the biological treatment drug, the biological treatment medicine is mRNA (messenger ribonucleic acid) coded biological macromolecules; the lectin is AAL, and the raw materials of the lipidosome nanoparticles comprise SM102, DSPC (Distearoyl Pyrrolidone), cholesterol, DMG-pSar25 and DSPE-PEG-MAL (Distearoyl Pyrrolidone-Polyethylene Glycol). According to the invention, AAL and LNP with specific components are coupled, so that specific recognition and binding with receptor fucose of target cells are realized, nano-materials are helped to be endocytosed through olfactory mucosa and delivered to the brain through a nasal-brain pathway, biological treatment drugs are delivered in a targeted manner, the blood-brain barrier is broken through, and the targeting efficiency and nasal delivery efficiency are remarkably improved.
Owner:TAIYI LIFE TECH (NINGBO) CO LTD

Lectin protein for treatment and prevention of neurodegenerative diseases

The present invention relates to the lectin protein for the treatment and prevention of neurodegenerative diseases. The invention further relates to the recombinant lectin protein is derived from Sclerotium rolfsii lectin having sequence 60% homologous to SEQ ID NO: 4 for the treatment and prevention of Neurodegenerative diseases. The invention specifically relates to lectin protein and its variants is derived from Sclerotium rolfsii lectin having sequence 60% homologous to SEQ ID NO: 4 for the treatment of prevention of Parkinson's disease, Alzheimer's disease, Dementia and symptoms of dementia.
Owner:UNICHEM LAB LTD

Normal-temperature bacteria liquid enteric-coated targeted colonization microcapsule and preparation method thereof

The invention discloses a normal-temperature bacteria liquid enteric-coated targeted colonization microcapsule and a preparation method thereof. The invention belongs to the technical field of biological medicine. The structure of the room-temperature bacterial liquid protection microcapsule is as follows: an inner layer is an activity maintaining layer and mainly consists of a sodium alginate-calcium chloride polyelectrolyte compound (the thickness is 50-100 microns); the middle layer is a pH response release layer and is mainly composed of hydroxypropyl methyl cellulose phthalate (HPMCP, dissolved at pH of 6.8 or above) and nano calcium carbonate particles (the particle size is 50nm, and the proportion is 10% w / w); the outer layer is a mucous membrane adhesion layer, and the main components of the mucous membrane adhesion layer comprise fucose modified chitosan (Fuc-CS, targeted colonic mucous membrane lectin protein) and carbomer 940 (pH sensitive adhesion polymer); the method is a microcapsule capable of preserving the bacterial liquid at normal temperature and accurately targeting colon release and adhesion colonization and a process thereof, the problem of flora activity loss caused by a freeze-drying process can be solved, in addition, the process does not need freeze-drying equipment, and the production cost is reduced.
Owner:BEIJING QINGSONG JINGCHUANG BIOTECHNOLOGY CO LTD

Recombinant fungal cells and methods thereof for industrial scale production of lectins

PCT designated stage expiredWO2025007098A1FungiPolypeptide with affinity tagHeterologousMicrobiology
The present disclosure is generally related to methods and compositions for producing heterologous lectin proteins of interest in recombinant filamentous fungal cells. Certain embodiments are therefore, directed to compositions and methods for the production of lectin proteins, recombinant filamentous fungal strains comprising enhanced lectin protein productivity phenotypes, polynucleotides (e.g., expression constructs) encoding one or more lectin proteins, industrial scale fermentation, lectin protein recovery processes and the like.
Owner:DANISCO US INC

Protein compositions for the treatment of inflammatory diseases

The present invention relates to the pharmaceutical compositions of lectin proteins and its use for the prevention, treatment and cure of inflammation, including inflammatory disease. The invention specifically relates to the pharmaceutical compositions for topical application comprising lectin proteins and its use for prevention, treatment and cure of inflammation due to chemotherapy and / or radiotherapy. The lectin may comprise an amino acid sequence having sequence of SEQ ID NO: 1 or at least 70% homology to SEQ ID NO: 1.
Owner:UNICHEM LAB LTD

Double-encapsulated lipid nanoparticles entering brain through nose as well as preparation method and application of double-encapsulated lipid nanoparticles

PendingCN120617545ANervous disorderKetone active ingredientsOlfactory Epithelial CellDrug encapsulation
The invention relates to double-encapsulated lipid nanoparticles entering brain through nose and a preparation method and application thereof, the double-encapsulated lipid nanoparticles comprise lipid nanoparticles, drugs in the lipid nanoparticles and rana odorata lectin coupled to the surfaces of the lipid nanoparticles, and the drugs comprise hydrophilic drugs and hydrophobic drugs. According to the invention, the rana odorata lectin and the lipid nanoparticles are coupled, and the rana odorata lectin can be specifically combined with L-fucose residues expressed by olfactory epithelial cells, so that the adhesion of the lipid nanoparticles to olfactory epithelium during nasal administration is enhanced, and the brain entering efficiency of the lipid nanoparticles is finally improved. After entering the brain, the lipid nanoparticles respond to diseased regions with high active oxygen content so as to release drugs. In addition, double-drug encapsulation can target different pathogenesis of central nervous system diseases, and the limitation that a traditional treatment drug is single in action target is improved.
Owner:CHINA NAT TOBACCO QUALITY SUPERVISION & TEST CENT

Process for the preparation of recombinant lectin protein

The present invention relates to the process to prepare recombinant lectin having amino acid sequence of SEQ ID NO:1, wherein the process comprises fed-batch fermentation of a clone in a host cell at specific feeding rate with carbon to Nitrogen ratio of 3:1 to 6:1. The invention also relates to the process of purification of recombinant lectin having amino acid sequence of SEQ ID NO: 1.
Owner:UNICHEM LAB LTD

Compositions and Methods of Chimeric Autoantibody Receptor Cells Expressing Extended Phospholipase A2 Receptor Fragments

The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor (BCR), polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells (e.g., T cells) comprising the CAAR, wherein the CAAR comprises a PLA2R autoantigen comprising an extended cysteine rich (eCysR) domain comprising (a) a PLA2R N-terminal peptide and a cysteine rich (CysR) domain, and (b) a C-type lectin domain 7 (CTLD7). The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R autoantigen comprising an extended cysteine rich (eCysR) domain comprising (a) a PLA2R N-terminal peptide and a cysteine rich (CysR) domain, and (b) a C-type lectin domain 7 (CTLD7).
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Combined medicine for preventing and / or treating prostatic cancer, application of combined medicine and pharmaceutical composition

The invention belongs to the field of chemical medicines, and particularly relates to a combined medicine for preventing and / or treating prostatic cancer, application of the combined medicine and a medicine composition. The combined medicine disclosed by the invention comprises immune cells with enhanced infiltration degree and a galectin-1 inhibitor; the immune cells with enhanced infiltration degree are natural killer (NK) cells with TTTY15-USP9Y chimera RNA knocked out, the infiltration degree and anti-tumor activity of the NK cells in a prostate cancer microenvironment can be improved, and the activated NK cells have a stronger killing effect on tumor cells in vitro. The immune cells with enhanced infiltration degree and the galectin-1 inhibitor are combined for use, so that the composition shows a synergistic effect in treatment of prostatic cancer, and has a wide application prospect.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Recombinant protein for SARS-COV2 disease

The present invention relates to the protein for treatment of infectious disease caused by Coronaviridae. In particular, the invention relates to a recombinant Sclerotium rolfsii lectin for use in the treatment, reduction in progression and curing of SARS-COV2 disease in a subject in need thereof. Pharmaceutical compositions comprising said recombinant Sclerotium rolfsii lectin are also described. The recombinant Sclerotium rolfsii lectin protein may comprise an amino acid sequence having at least 70% homology to SEQ ID NO: 1.
Owner:UNICHEM LAB LTD

Protein for treatment of inflammatory diseases

The present invention relates to a lectin for use in the treatment, reduction in progression and curing of inflammation in a subject in need thereof. Pharmaceutical compositions comprising said lectin are also described. The lectin may comprise an amino acid sequence having sequence of SEQ ID NO: 1 or at least 60% homology to SEQ ID NO: 2.
Owner:UNICHEM LAB LTD

Compositions of nucleic acid nanostructures for vaccines and methods of use thereof

Compositions containing a nucleic acid nanostructure having a desired geometric shape and an antigen and / or immunostimulatory agent(s) bound to its surface are provided. The nanostructure design allows for control of the relative position and / or stoichiometry of the immunostimulatory agent(s) bound to its surface. The antigen and / or immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be eOD-GT8. The immunostimulatory agent can be, e.g., T cell epitope such as a pan HLA DR-binding epitope (PADRE) and / or a lectin such as MBL or C3, or ligand thereof such as a glycan including mannose. Also provided are antigen-T cell epitope fusions such as eOD-PADRE and nanostructures presenting the same. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses are also provided.
Owner:MASSACHUSETTS INST OF TECH

Trop2 antibodies

Provided herein are anti-Trop 2 antibodies or binding fragments thereof that bind Trop 2, e.g., human Trop 2. The anti-Trop 2 antibodies of the disclosure are useful for the treatment of proliferative disorders or cells that express Trop 2 or mutant Trop 2. Also provided herein are methods of use for the anti-Trop 2 antibodies or binding fragments thereof, as well as bi-valent or multi-valent anti-Trop 2 antibodies or binding fragments thereof that may form complexes that attract immune effectors or binding to other cells, such as, a second antibody, antigen-binding of the second antibody or fragment thereof; a target-binding protein, a cytokine; a lectin; or a toxin.
Owner:IBIO INC

A method for the analysis of glycans on individual extracellular vesicles in a fluid sample

The application belongs to the technical field of biology and specifically relates to a method for analyzing glycans on single extracellular vesicles in a fluid sample. The method uses magnetic nanoparticles to capture and manipulate EVs, based on the specific affinity of lectins for specific glycan structures, uses polydisperse microdroplets to separate the captured EVs, realizes local signal amplification in the droplets through enzymatic reaction, adopts fluorescence microscopy to collect images of the droplets, and thus realizes identification and analysis of the glycan components on single EVs. The preparation process of the microdroplets formed by the oscillating emulsification method of the application makes the entire detection process more simple and fast, does not require any microfluidic chip and special device, and can be completed in a centrifugal tube, and all the microdroplets are generated in parallel and quickly, and the amount of microdroplets can be flexibly expanded. Moreover, compared with the traditional ELISA, the method has high sensitivity, low detection limit and small sample consumption.
Owner:WENZHOU INST UNIV OF CHINESE ACAD OF SCI

Inhibition of endosomal escape detection to ameliorate the inflammatory side-effects of lipid nanoparticles

PCT designated stage expiredWO2025128913A1Powder deliveryTetrapeptide ingredientsSide effectMedicine
Composition and methods for preventing or reducing inflammation resulting from nanoparticle administration to a subject are provided. In one embodiment a method of delivering an agent to a target organ of a subject, comprises administering to the subject a galectin inhibitor and a nanoparticle comprising the agent, wherein inflammation resulting from administration of the nanoparticle is reduced or prevented.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Multispecific antibodies and uses thereof

This disclosure relates to anti-CLEC5A (C-type lectin domain family 5 member A) antibodies, antigen-binding fragments thereof. This disclosure relates to an antibody or antigen-binding fragment thereof, comprising a first antigen-binding domain that specifically binds to a tumor associated antigen (TAA) and a second antigen-binding domain that specifically binds to CLEC5A, and an Fc region.
Owner:LTZ THERAPEUTICS INC

Methods of inhibiting MASP-2 for the treatment and / or prevention of coronavirus-induced acute respiratory distress syndrome

In one aspect, the invention provides methods for treating, inhibiting, alleviating, or preventing acute respiratory distress syndrome, pneumonia, or some other pulmonary or other manifestation of coronavirus infection, such as thrombosis, in a mammalian subject infected with coronavirus, such as SARS-CoV-2. The methods comprise the step of administering to a subject infected with coronavirus an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In one embodiment, the MASP-2 inhibitory agent is a MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6. In one embodiment, the MASP-2 inhibitory agent is a small molecule MASP-2 inhibitory compound. In one embodiment, the subject is a human subject suffering from COVID-19-induced acute respiratory distress syndrome (ARDS) and requires supplemental oxygen prior to treatment and the MASP-2 inhibitory agent is administered in an amount sufficient to discontinue the need for supplemental oxygen.
Owner:OMEROS CORP

Double-stranded siRNA analogue for inhibiting MASP2 expression as well as preparation method and application of double-stranded siRNA analogue

The present invention relates to a double-stranded siRNA analogue for inhibiting expression of mannan-binding lectin-related serine protease 2 (MASP2), and a preparation method and use thereof, the double-stranded siRNA analogue can inhibit expression of MASP2, and is used for preventing and / or treating MASP2-related diseases and symptoms, such as MASP2-related diseases and disorders. The diseases and symptoms comprise IgA nephropathy, membranous nephropathy, lupus nephritis, thrombotic microangiopathy, systemic lupus erythematosus and the like.
Owner:SHENZHEN SALUBRIS PHARMA CO LTD

Application of primer for detecting anti-disease gene of Eriocheir sinensis in identification of parent disease resistance of Eriocheir sinensis

The application of the primer for detecting the anti-disease gene of the Eriocheir sinensis in identifying the disease resistance of the parent of the Eriocheir sinensis comprises the following steps: (1) respectively extracting RNA (Ribonucleic Acid) of the Eriocheir sinensis, and carrying out reverse transcription to obtain cDNA (Complementary Deoxyribonucleic Acid) of the Eriocheir sinensis; (2) designing a primer combination according to the sequence of the lysozyme gene of the eriocheir sinensis and the sequence of the C-type lectin 4 gene, performing PCR amplification on the cDNA sample of the eriocheir sinensis by utilizing the primer combination to obtain a target fragment, and detecting and confirming that the target fragment is amplified by utilizing agarose gel electrophoresis; (3) obtaining a cDNA sequence by a first-generation sequencing means, carrying out sequence comparison, identifying SNP sites in gene coding regions of the lysozyme gene and the C-type lectin 4 gene, and analyzing the two genes and a combination thereof; and comparing the differences of the disease resistance of the genotypes, and screening to obtain the genotype with the strongest disease resistance and the combined marker primer thereof.
Owner:SUQIAN AGRI SCI RES INST JIANGSU ACAD OF AGRI SCI

Methods of treating t-cell large granular lymphocytic leukemia

PCT designated stageWO2026072990A1Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenLarge granular lymphocytic leukemia
The present disclosure relates to methods of treating T-cell large granular lymphocytic leukemia (T-LGLL) with antibodies, or antigen-binding fragments thereof, that specifically bind to killer cell lectin-like receptor G1 (KLRG1), and methods for maintaining remission of T-cell large granular lymphocytic leukemia in a patient.
Owner:ABCURO INC

Antrodia camphorata sporocarp extract

The invention provides an antrodia camphorata sporocarp extract, which is prepared from the following raw materials in parts by weight: 20 to 24 parts of wild ganoderma lucidum extract, 8 to 12 parts of herba taraxaci and 8 to 12 parts of bolete. The antrodia camphorata sporocarp extract disclosed by the invention contains various physiologically active components such as triterpenoids, polysaccharides, superoxide disproportionated enzymes, adenosine, proteins (containing immune proteins), vitamins, trace elements, nucleic acid, lectin, amino acid, sterols, lignin, blood pressure stabilizing substances and the like; the traditional Chinese medicine composition can relieve various tumors such as hangover, gastrointestinal discomfort, heatstroke, hypertension, virus infection, diabetes mellitus, nephritis, liver cirrhosis and liver cancer, has the effects of resisting oxidation, resisting inflammation, inhibiting hypertension, protecting liver nerves, inhibiting tumor growth and the like, can bidirectionally regulate immunity and protect the liver, can also treat tumors at multiple targets, and has a wide application prospect. The discomfort of a patient in an anti-tumor process is reduced.
Owner:TIANJIN CLOUD LADDER ENTERPRISE MANAGEMENT CONSULTING CO LTD

Compositions and methods for industrial scale production and recovery of lectins

Certain aspects of the present disclosure relate to industrial scale production and recovery of lectin proteins. Certain aspects relate to recombinant gram-positive bacterial cells that produce heterologous lectin proteins. Certain other aspects relate to compositions and methods for recovering and / or purifying one or more lectins and lectin formulations with improved purity thereof.
Owner:DANISCO US INC

Chimeric antigen receptors targeting abnormal glycobiology

The disclosure provides a chimeric antigen receptor (CAR) polypeptide having an antigen binding domain comprising an extracellular lectin which specifically binds to glycoproteins expressed on the surface of target cells. Also provided herein are engineered lymphocytes expressing the CAR polypeptide, a nucleic acid molecule encoding the CAR polypeptide, and methods of treating cancer.
Owner:THE RGT UNIV OF MICHIGAN

A marker combination and its use in the diagnosis of active tuberculosis and in the differentiation between latent tuberculosis infection and active tuberculosis

The present application relates to the technical field of diagnostic markers, in particular to a marker combination and its application in diagnosing active tuberculosis and distinguishing between latent tuberculosis infection and active tuberculosis. The lectin combination provided by the present application can be used as a marker for ATB diagnosis and distinguishing between LTBI and ATB, and has high specificity and sensitivity. The lectin combination provided by the present application in combination with detection of specific antibodies of mycobacterium tuberculosis antigens can further improve the diagnostic effect. The marker and its detection products provided by the present application have good application potential in ATB diagnosis and distinguishing between LTBI and ATB, and are expected to overcome the limitations of existing diagnostic techniques, improve the diagnostic accuracy and sensitivity of tuberculosis, and provide new ideas and technical means for early detection, precise treatment and effective prevention and control of tuberculosis.
Owner:GUANGZHOU NAT LAB